Activity of ceftazidime-avibactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status.
Autor: | Johnston BD; VA Medical Center, Minneapolis, MN; University of Minnesota, Minneapolis, MN. Electronic address: john5041@umn.edu., Thuras PD; VA Medical Center, Minneapolis, MN; University of Minnesota, Minneapolis, MN., Johnson JR; VA Medical Center, Minneapolis, MN; University of Minnesota, Minneapolis, MN. |
---|---|
Jazyk: | angličtina |
Zdroj: | Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2020 Jul; Vol. 97 (3), pp. 115034. Date of Electronic Publication: 2020 Mar 10. |
DOI: | 10.1016/j.diagmicrobio.2020.115034 |
Abstrakt: | Escherichia coli ST131, with its multidrug-resistance-associated H30R1 and H30Rx clonal subsets within the H30R subclone, causes most antimicrobial-resistant E. coli infections. The activity of ceftazidime-avibactam (CZA) against ST131 strains is undefined. We determined CZA MICs for 595 E. coli clinical isolates from 24 Veterans Affairs Medical Centers (2010-2011). Resistance status and MICs were compared with study resistance category (fluoroquinolone-susceptible, fluoroquinolone-resistant, and extended-spectrum beta-lactamase (ESBL)-producing); ST131, H30R1, and H30Rx status; bla (Copyright © 2020 Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |